pcn poster

Posters

How Patients with Depression and their Providers Navigate Anhedonia: An Ethnographic Evaluation of Discourse Dynamics of Psychiatrists and Primary Care Providers in Clinical Settings

Abstract: Background Anhedonia, a key symptom of major depressive disorder (MDD), impacts patients' quality of life and treatment outcomes. However, limited research exists on healthcare ...

08/20/2024

Effectiveness of Deutetrabenazine for Tardive Dyskinesia When Initiated Using a 4-Week Patient Titration Kit: Final Results of the START Study

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor for the treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)–related c...

08/20/2024

Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomized controlled trial program

Abstract: Rationale No effective pharmacological treatments are available for cognitive impairments in schizophrenia. Iclepertin (BI 425809), a glycine transporter-1 inhibitor, enhances N...

08/20/2024

Enhancing Behavioral Health Workforce: Evaluating the Impact of an HRSA-Funded Interprofessional Training Initiative

Abstract: This research analyzes the outcomes of a federal training grant first awarded in 2017 by the Health Resources and Services Administration (HRSA) to address the shortage of behav...

08/20/2024

Attitudes DriVing regional differences in LAI Antipsychotic utilization for schizophrenia among HCPs, patients, and CaregivErs (ADVANCE) Study: Patients’ Perspectives on Initial and Current Treatments

Abstract: Background: For patients with schizophrenia, long-acting injectable (LAI) antipsychotics can reduce relapse and hospitalization rates and improve adherence versus oral antipsych...

08/20/2024

Establishment of a digital therapeutic alliance in patients living with negative symptoms of schizophrenia

Abstract: Introduction: A patient-digital therapeutic (DTx) bond (digital working alliance [DWA]) may be important for DTx success. We assessed whether patients with experiential negative...

08/20/2024

AXS-05 (Auvelity) in Major Depressive Disorder: Pooled Data From Two Six-Week Controlled Trials (GEMINI and ASCEND)

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion; Auvelity) is a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved for treating ...

08/20/2024

Challenges and Approaches for Managing Psychosis in Advanced Parkinson's Disease: A Case Report

Abstract: Parkinson's Disease (PD) psychosis poses major treatment challenges due to the delicate balance required between managing motor deficits and psychotic symptoms. Treating PD asso...

08/20/2024

Changes in Neuroplasticity Related to Nonpharmacological Interventions for Major Depressive Disorder: A Systematic Literature Review

Abstract: Introduction: People with major depressive disorder (MDD) have impaired neuroplasticity. Antidepressant treatment and some nonpharmacological interventions can lead to changes i...

08/20/2024

Clinical Effectiveness of Esketamine for Treatment-Resistant Depression: A Real-World Study of Patients in Mindful Health Solutions Clinics

Abstract: BACKGROUND: To generate real-world evidence of esketamine effectiveness for treatment resistant depression (TRD), this study assessed change in depressive symptoms after esketam...

08/20/2024

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products